Good morning, you're listening to Markets Desk.
Two hundred and fifty years after the Declaration of Independence, a long look at American markets tells a compelling story. Since seventeen seventy-six, U.S. stocks have returned an average of eight point seven percent annually — a figure that, compounded across generations, explains why equity ownership became the bedrock of American wealth-building.
Shifting to the energy sector, NuScale Power has shed roughly three quarters of its value over the past twelve months, and that decline reflects something deeper than sentiment. The company holds the only federally certified small modular reactor design in the country, but rising construction cost estimates and project cancellations have left investors questioning whether the economics of nuclear's next generation can actually pencil out in the near term.
On the biotech side, Viking Therapeutics had a strong June, with shares climbing on sustained enthusiasm around its weight-loss drug candidate VK two seven three five. Investors believe Viking's compound offers meaningful advantages over existing GLP-one therapies, and with Phase three trial results anticipated in the coming years, the market is pricing in considerable optimism well ahead of the data.
That's the tape. Markets Desk, signing off the floor.
